Ocular Myasthenia Gravis
Neurology·MeSH: Myasthenia Gravis
Prevalence
5.0 / 100K
2 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
Phase 2(1)
| Drug | Company |
|---|---|
| rozanolixizumab | GT Biopharma, Inc. (GTBP) |
Frequently asked questions
How many drugs are in development for Ocular Myasthenia Gravis?
BioSniper tracks 2 drugs in development for Ocular Myasthenia Gravis across 2 companies.
How many clinical trials target Ocular Myasthenia Gravis?
There are 2 clinical trials targeting Ocular Myasthenia Gravis tracked by BioSniper.
What is the prevalence of Ocular Myasthenia Gravis?
The estimated prevalence of Ocular Myasthenia Gravis is approximately 5.0 per 100,000 population.
Deep-dive into Ocular Myasthenia Gravis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis